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Background: The effectiveness of lipid-lower-
ing medication critically depends on the patients’
compliance and the efficacy of the prescribed
drug.
Objectives: The primary objective of this mul-
ticentre study was to compare the efficacy of rosu-
vastatin with or without access to compliance ini-
tiatives, in bringing patients to the Joint Euro-
pean Task Force’s (1998) recommended low-den-
sity lipoprotein cholesterol (LDL-C) level goal
(LDL-C, <3.0 mmol/L) at week 24. Secondary
objectives were comparison of the number and
percentage of patients achieving European goals
(1998, 2003) for LDL-C and other lipid parame-
ters.
Patients and methods: Patients with primary
hypercholesterolaemia and a 10-year coronary
heart disease risk of >20% received open label ro-
suvastatin treatment for 24 weeks with or without
access to compliance enhancement tools. The ini-
tial daily dosage of 10 mg could be doubled at
week 12. Compliance tools included: a) a starter
pack for subjects containing a videotape, an edu-
cational leaflet, a passport/goal diary and details
of the helpline and/or website; b) regular person-
alised letters to provide message reinforcement; 
c) a toll-free helpline and a website.
Results: The majority of patients (67%)
achieved the 1998 European goal for LDL-C at
week 24. 31% required an increase in dosage of
rosuvastatin to 20 mg at week 12. Compliance en-
hancement tools did not increase the number of
patients achieving either the 1998 or the 2003
European target for plasma lipids. Rosuvastatin
was well tolerated during this study. The safety
profile was comparable with other drugs of the
same class. 63 patients in the 10 mg group and 58
in the 10 mg Plus group discontinued treatment.
The main reasons for discontinuation were ad-
verse events (39 patients in the 10 mg group; 35
patients in the 10 mg Plus group) and loss to fol-
low-up (13 patients in the 10 mg group; 9 patients
in the 10 mg Plus group). The two most fre-
quently reported adverse events were myalgia (34
patients, 3% respectively) and back pain (23 pa-
tients, 2% respectively). The overall rate of tem-
porary or permanent study discontinuation due to
adverse events was 9% (n = 101) in patients re-
ceiving 10 mg rosuvastatin and 3% (n = 9) in pa-
tients titrated up to 20 mg rosuvastatin.
Conclusions: Rosuvastatin was effective in low-
ering LDL-C values in patients with hypercholes-
terolaemia to the 1998 European target at week
24. However, compliance enhancement tools did
not increase the number of patients achieving any
European targets for plasma lipids. 
Key words: statin; rosuvastatin; hypercholesterol -
aemia; LDL-C, triglycerides; compliance 
Summary
Coronary heart disease (CHD) is the leading
cause of death in high-income countries [1].
Major risk factors for CHD are cigarette smok-
ing, elevated blood pressure, elevated serum total
cholesterol (TC) and low-density lipoprotein
cholesterol (LDL-C), low serum high-density
lipoprotein cholesterol (HDL-C), diabetes melli-
tus, and advancing age [2, 3]. A positive correla-
tion was observed between plasma levels of TC or
LDL-C and the risk of developing CHD [4].
Introduction
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Clinical trials of lipid modification either by diet
or drugs have shown that CHD risk associated
with elevated cholesterol can be substantially re-
duced [5].
Guidelines for the management of risk factors
influencing CHD were initially based on large-
scale epidemiological surveys conducted in the
USA. After similar studies in other countries it
became apparent that there were significant in-
consistencies in the assessment of risk for CHD,
and in the LDL-C or TC threshold levels indicat-
ing lipid lowering treatment [6]. In 1998 the Sec-
ond Joint Task Force of European and other Soci-
eties issued recommendations on goals for LDL-
C (<3.0 mmol/L) and TC levels (<5.0 mmol/L)
[5]. These recommendations applied to patients
with CHD (or other atherosclerotic disease) and
patients with a 10-year CHD risk 020% either at
their present age or when projected to age 60 [5]. 
New guidelines were issued by the Third
Joint Task Force of European and other Societies
in 2003 [7]. For asymptomatic patients with a 10-
year risk of a fatal coronary event <5%, these
guidelines contain the same goals for plasma
LDL-C (<3.0 mmol/L) and TC (<5.0 mmol/L) as
those recommended in 1998 [5, 7]. However, for
patients with clinically established cardiovascular
disease (CVD), diabetes or a 10-year risk of a fatal
coronary event >5%, the new guidelines recom-
mend lower goals for LDL-C (<2.5 mmol/L) and
TC levels (<4.5 mmol/L) [7]. 
Statins (HMG-CoA reductase inhibitors)
have been shown to be highly effective in reduc-
ing the level of LDL-C and the rate of major
coronary events, and in improving overall survival
in patients with CHD [8–11]. Moreover, statins
are well tolerated and are cost-effective in sec-
ondary prevention of CHD [12–14]. Rosuvastatin
is a highly potent statin that effectively reduces
LDL-C in patients with hypercholesterolaemia
[15].
Compliance is a complex behavioural process
and is strongly influenced by the environment,
the healthcare provider’s practice, and the care de-
livery system [16, 17]. Several clinical trials have
shown suboptimal compliance with lipid-lower-
ing therapy with statins [18–20]. Achieving a high
level of compliance presupposes that the patient
has the requisite knowledge, motivation and re-
sources to follow treatment recommendations.
Several approaches may be considered to improve
compliance, the most promising being combina-
tions of interventions involving, amongst other
things, patient education, self-monitoring, social
support and telephone follow-up [21–24]. 
The primary objective of this study was to
compare the efficacy of treatment with rosuvas-
tatin, with or without access to compliance initia-
tives, in bringing patients to the Joint European
Task Force (1998) recommended LDL-C goal
(<3.0 mmol/L).
Patients and methods
Trial design
This was a cluster-randomised, multicentre, open
label, parallel group study of 24 weeks’ duration and con-
ducted throughout Switzerland. A cluster randomisation
procedure was used and all patients in each centre were
assigned to the same treatment group.
Patients
Patients (018 years) attending primary care physician
practices for treatment of primary hypercholesterolaemia
with a 10-year CHD risk >20% (as defined by the 1998
European Guidelines [5]), CHD or other atherosclerotic
disease were eligible for the study. The patients were
statin naïve or on an accepted starting dose of lipid-low-
ering medication, which had proved ineffective in reach-
ing the target level of LDL-C for that dose. Statin naïve
patients (with an LDL-C >3.5 mmol/L fasting level) were
required to complete dietary counselling before entering
the study. Patients who switched from accepted starting
doses of other lipid-lowering medication (with an LDL-
C >3.1 mmol/L fasting level) were directly enrolled in the
study. Another inclusion criterion was a fasting triglyc-
eride (TG) level of 94.52 mmol/L. 
Patients were excluded from the study if they were
known to have heterozygous or homozygous familial hy-
percholesterolaemia, type III hyperlipoproteinaemia (fa-
milial dysbetalipoproteinaemia), or secondary hypercho-
lesterolaemia. Those known to have hypersensitivity re-
actions or serious adverse effects (eg. myopathy) in rela-
tion to other statins were also excluded. Pregnant or
breast feeding women were excluded, whilst women of
child bearing potential were asked to use adequate con-
traception during the study. Other exclusion criteria in-
cluded unstable cardiovascular disease, uncontrolled dia-
betes, active liver disease, renal impairment as defined by
a serum creatinine level >220 mmol/L, any medical condi-
tion requiring cyclosporine therapy, and a history of alco-
hol and/or drug abuse.
The study was conducted in accordance with Good
Clinical Practice Guidelines and local law. The study pro-
tocol was approved by the appropriate ethics committees.
Written informed consent was obtained from each pa-
tient.
Study procedure
Patients received a daily oral treatment with either
rosuvastatin alone (10 mg group) or with rosuvastatin and
access to compliance enhancement tools (10 mg Plus
group) for 24 weeks. Patients were assessed at week 4 and
at week 12 to review fasting levels of TC, LDL-C, HDL-
C, and triglycerides. For patients not achieving the 1998
European target for LDL-C at week 12 the daily dose of
rosuvastatin was increased to 20 mg for the remainder of
the study. Patients in the 10 mg Plus group received a
starter pack containing a videotape and educational
leaflets concerning their condition. These patients also
received newsletters at regular intervals and had access to
both a telephone helpline and an Internet website, all de-
signed to reinforce the initial message in the starter pack. 
Rosuvastatin tablets were dispensed to all patients
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during the first study visit (week 0) and at week 12. Pa-
tients were asked to return all unused rosuvastatin tablets
and containers to the investigator at week 12 and week
24. The Patient’s compliance was determined by the dif-
ference between the dispensed and the returned tablets in
comparison with the number of days between the visits.
The dropout patients were not considered for the com-
pliance assessment. Only the data from the patients who
completed the whole protocol were taken into account.
Efficacy and safety endpoints
The primary efficacy endpoint was the number and
percentage of patients in both treatment groups who
reached the 1998 European goal for LDL-C (<3.0
mmol/L) after 24 weeks of therapy. Secondary efficacy
endpoints included the number and percentage of pa-
tients within the 1998 European goal for LDL-C at week
12, the number and percentage of patients within the
1998 European goal for TC (<5.0 mmol/l) at week 12 and
week 24, and the number and percentage of patients
within the 2003 European goal for LDL-C (<2.5
mmol/L) and for TC (<4.5 mmol/L) at week 12 and week
24. Other secondary efficacy endpoints were the number
of patients with a dose increase to 20 mg rosuvastatin at
week 12; the percentage change in LDL-C, TC, HDL-C,
and TG between baseline and week 24; and the patient’s
compliance as measured by tablet count for both treat-
ment groups. 
Safety assessment included adverse events reporting,
clinical chemistry measurements and physical examina-
tions.
Statistical methods
Efficacy analyses were performed on data from the
intention to treat (ITT) population which included pa-
tients who received 01 doses of drug and had 01 post-
baseline lipid values. The last observation was carried for-
ward (LOCF) for missing efficacy data at week 24. All
analyses performed at week 12 were based upon observed
data (OC). All patients who received at least one dose of
rosuvastatin were included in the safety population.
Comparisons were performed between treatment groups
using logistic regression analysis. The number of patients
achieving the EAS LDL-C target was analysed using a
logistic analysis, with terms included in the model for pa-
tient type (naïve or switched), treatment group (only ro-
suvastatin or rosuvastatin plus compliance tool) and the
interaction between treatment group and patient type.
The interaction term was found to be not statistically sig-
nificant (change in -2logL = 0.608, p-value = 0.4356) and
was dropped from the final model. The adjusted odds ra-
tios derived from the final model and their 95% CI (esti-
mated from the likelihood ratio method) were shown
with corresponding p-values. Statistical significance was
accepted at the 5% level. 
Results
Patient demographics
A total of 1128 patients were randomised to
the two treatment groups, 601 patients to rosuvas-
tatin alone (10 mg group), 527 patients to rosuvas-
tatin with access to compliance enhancement
tools (10 mg Plus group). All 1128 patients were
part of the safety population. A total of 126 pa-
tients failed to provide a lipid sample at baseline
or at least one lipid sample post-baseline and were
excluded from the efficacy analyses. Data for 
1002 patients (531 patients in the 10 mg group;
471 patients in the 10 mg Plus group) were 
therefore available for the efficacy analyses (ITT
population). Demographic characteristics of the
ITT population entering the study are shown in
table 1. 
Treatment group Rosuvastatin Rosuvastatin with Total
alone compliance enhancement  
(10 mg) tools (10 mg Plus)
ITT population N 531 471 1002
Demographic characteristics
Gender Male 309 (58%) 303 (64%) 612 (54%)
Female 222 (42%) 168 (36%) 390 (35%)
Age (years) Mean (± SD) 60 (± 11.1) 60 (± 11.2) 60 (± 11.1)
Baseline characteristics
Statin naïve patients N (%) 274 (52%) 241 (51%) 515 (51%)
Statin switched patients N (%) 257 (48%) 230 (49%) 487 (49%)
TC (mmol/l) Mean (± SD) 7.0 (± 1.13) 7.0 (± 1.18) 7.0 (± 1.15)
LDL-C (mmol/l) Mean (± SD) 4.7 (± 1.04) 4.7 (± 1.09) 4.7 (± 1.07)
TG (mmol/l) Mean (± SD) 2.1 (± 0.93) 2.1 (± 0.86) 2.1 (± 0.90)
HDL-C (mmol/l) Mean (± SD) 1.3 (± 0.34) 1.4 (± 0.32) 1.3 (± 0.33)
Important risk factors
Coronary heart disease N (%) 144 (27%) 141 (30%) 285 (28%)
Atherosclerotic disease N (%) 195 (37%) 186 (39%) 381 (38%)
Diabetes mellitus N (%) 85 (16%) 82 (17%) 167 (17%)
Hypertension N (%) 344 (65%) 302 (64%) 646 (64%)
Smoking N (%) 308 (58%) 275 (58%) 583 (58%)
Notes: Total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), triglycerides (TG), 
and high density lipoprotein cholesterol (HDL-C). 
Table 1
Demographic and
baseline characteris-
tics of the ITT popula-
tion.
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Figure 1
Percentage of sub-
jects achieving the
European goals at
week 24 (LOCF) and
week 12 (OC) in pa-
tients treated with 
rosuvastatin alone
(10 mg group) or in
combination with
compliance enhance-
ment tools (10 mg
Plus group).
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Week 24 Week 12 Week 24 Week 12
MedDRA preferred term Rosuvastatin Rosuvastatin
10 mg (N = 1128) 20 mg (N = 334)
n (%) n (%)
Myalgia 32 (3) 2 (1)
Back pain 21 (2) 2 (1)
Bronchitis 16 (1) 6 (2)
Headache 21 (2) 0 (0)
Nausea 15 (1) 4 (1)
Blood creatinine kinase increased 15 (1) 3 (1)
Arthralgia 16 (1) 1 (0)
Depression 14 (1) 2 (1)
Influenza 15 (1) 0 (0)
Constipation 14 (1) 0 (0)
Vertigo 12 (1) 2 (1)
Abdominal pain upper 12 (1) 1 (0)
Table 2
Proportion of patients
in the safety popula-
tion with the most
commonly reported
adverse events (≥1%)
according to dose of
rosuvastatin at onset.
A
B
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121 patients (63 patients in the 10 mg group;
58 patients in the 10 mg Plus group) discontinued
treatment during the study. The main reasons for
discontinuation were adverse events (39 patients
in the 10 mg group; 35 patients in the 10 mg Plus
group) and loss to follow-up (13 patients in the 10
mg group; 9 patients in the 10 mg Plus group). 
Patients in both treatment groups received
rosuvastatin for similar periods of time. The mean
duration of treatment was 177 days for patients in
the 10 mg group and 174 days for those in the 10
mg Plus group. At week 12, 309 patients (31%) in
the ITT population (162 patients in the 10 mg
group; 147 patients in the 10 mg Plus group),
were titrated up to 20 mg rosuvastatin. 
Primary efficacy analysis
In the 10 mg group, 67% of patients (358)
achieved the 1998 European LDL-C goal (<3.0
mmol/L) at week 24 (LOCF) compared to 61%
of patients (286) in the 10 mg Plus group, as
shown in Figure 1. A patient assigned to the 10
mg Plus treatment group has 0.74 (95% CI 0.60-
0.97; p = 0.032) lower odds of achieving the target
than a patient assigned to the 10 mg (alone)
group. 
Secondary efficacy analyses
In the 10 mg group, 62% (316 patients)
achieved the 1998 European LDL-C goal at week
12 (OC), compared to 61% (272 patients) in the
10 mg Plus group (figure 1) (difference not statis-
tically significant (ns)). Patients in both treatment
groups were found to have the same likelihood of
achieving either the 1998 European LDL-C goal
or the 2003 European LDL-C goal (<2.5
mmol/L) at week 12 and week 24. Similar find-
ings were obtained for the 1998 European TC
goal (<5.0 mmol/L) at week 12 and week 24, and
for the 2003 European TC goal (<4.5 mmol/L) at
week 12 and week 24.
There were favourable changes in lipid levels
from baseline to week 24 (figure 2). Mean per-
centage decrease from baseline to week 24 in
LDL-C, TC and TG levels were similar for both
treatment groups (ns). LDL-C, TC and TG de-
creased in the 10mg group by 37.3%, 26.4% and
11.4% respectively and in the 10mg Plus group
by 37.2%, 26.1% and 9.8% respectively. In gen-
eral, higher reductions in LDL-C, TC and TG
levels were reported for statin-naïve patients in
comparison with those who switched from other
lipid-lowering medication A statin-switched pa-
tient has 0.38 (95%; CI 0.29–0.51; p = 0.0001)
lower odds of achieving the EAS LDL-C target
than a statin-naïve patient. In the 10 mg group,
75.5% of statin-naïve vs. 58.8% of switched pa-
tients achieved the primary endpoint, compared
to 66.4% statin-naïve vs. 54.8% of switched pa-
tients in the 10 mg Plus group.
Patient compliance with treatment was re-
ported as high, with mean values of 97% (10 mg
group) and 100% (10 mg Plus group) between
week 12 and week 24. 
Safety and tolerability
Table 2 shows the common adverse events oc-
curring in more than 1% of patients. The two
most frequently reported adverse events were
myalgia (34 patients, 3% respectively) and back
pain (23 patients, 2% respectively). The overall
rate of temporary or permanent study discontinu-
ation due to adverse events was 9% (n = 101) in
patients receiving 10 mg rosuvastatin and 3% (n =
9) in patients titrated up to 20 mg rosuvastatin.
74 patients reported serious adverse events
(SAEs). The two most common SAEs were my-
ocardial infarction (4 patients) and angina pec-
toris (3 patients). One patient died from a sudden
cardiac event while receiving 20 mg rosuvastatin.
According to the investigator the death of this 
patient was not treatment-related. 6 patients ex-
perienced SAEs for which a causal relation with
rosuvastatin therapy was suspected. These SAEs
were hepatitis (1 patient), creatinine elevation 
(2 patients), dyspnoea (1 patient), muscle pain 
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Figure 2
Mean percentage
change in plasma
lipids between base-
line and week 24 in
patients treated with
rosuvastatin alone
(10 mg group) or in
combination with
compliance enhance-
ment tools (10 mg
Plus group).
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(1 patient), and blood pressure elevation (1 pa-
tient).
Changes in clinical laboratory parameters
were generally minor. Three patients experienced
clinically important creatinine (>upper limit of
normal and >100% over baseline) elevations.
Three patients had clinically important ASAT and
ALAT elevations (>3x the upper limit of normal).
There were no patients with a clinically impor-
tant increase of creatine kinase (>10x upper limit
of normal).
There were no clinically significant changes
in body weight, blood pressure and heart rate of
patients during the study.
Discussion
Statins (HMG-CoA reductase inhibitors) are
effective therapeutic agents for reducing plasma
lipid levels and lowering cardiovascular morbidity
and mortality in patients with CHD. Evidence
from multiple clinical trials suggests that rosuvas-
tatin offers the highest lipid-lowering efficacy at
the lowest dose for the treatment of patients with
hyperlipidaemia [25–27]. It is suggested that this
lipid-lowering efficacy is based on the higher
affinity of rosuvastatin to HMG-CoA reductase
compared with other statins including atorvas-
tatin, simvastatin and pravastatin [28].
In this study up to 67% of the patients treated
with rosuvastatin reached the 1998 European goal
for LDL-C (<3.0 mmol/L) at week 24. This was
achieved although the initial dosage of 10mg ro-
suvastatin had to be increased to 20 mg in only
31% of patients. These findings differed from
similar studies where as many as 74–88% of the
patients achieved the 1998 European goal for
LDL-C during treatment with a 10 mg daily dose
of rosuvastatin [27, 30–32]. However, baseline lev-
els of TC and LDL-C were higher in this study
than in other similar studies and 49% of the pa-
tients were already pre-treated with another
statin. This could explain why fewer patients
achieved the 1998 European goal and is supported
by data showing that reductions in levels of LDL-
C in patients in this study were similar to reduc-
tions reported in other studies. 
Rosuvastatin effectively reduced the mean
plasma levels of LDL-C in patients who were 
either statin naïve or had switched from other
lipid-lowering medication by 49.2% and 31.2%
respectively. The mean reduction in LDL-C was
comparable with findings from other studies
showing reductions of 42–52% with 5 mg or 10
mg daily doses of rosuvastatin [26, 33].
The reduction in TC and TG levels and 
increase in HDL-C levels achieved with rosuvas-
tatin in this study was comparable to those re-
ported in other studies [26, 27, 34].
The reductions in LDL-C, TC and TG levels
were generally higher for statin naïve patients
than for those switched from other lipid-lowering
medication. Moreover, statin naïve patents treated
with rosuvastatin showed a greater increase in
HDL-C levels compared to those switched from
other lipid-lowering medication. These changes
in the level of plasma lipids were in agreement
with observations other studies [34]. 
The effectiveness of lipid-lowering therapy
crucially depends on the patient’s compliance [35],
which was determined by counting tablets during
the study. Excellent compliance with treatment
was indicated by mean values of 97% (10 mg
group) and 100% (10 mg Plus group) between
week 12 and week 24. It is unusual that compli-
ance proportions of 100% are achieved in clinical
trials. This may be due to missing values resulting
from unreturned medication. It was assumed that
all the unreturned tablets had been taken.
Compliance enhancement initiatives em-
ployed during the present study were not found to
increase the number of patients achieving 1998 or
2003 European goals for plasma lipids. However,
this may be explained by the fact that patients in
both groups were already very compliant with
their treatment regimens. Moreover, patients par-
ticipating in a clinical trial are more likely to be
compliant with their treatment than in real life –
regardless of which treatment group they are in.
Rosuvastatin was generally well tolerated.
The adverse events and safety profile for rosuvas-
tatin were similar to that of other statins [36].
Myalgia was the most commonly reported adverse
event, affecting 3% of patients. 
This study shows that rosuvastatin was effec-
tive in reducing LDL-C in the majority of pa-
tients with hypercholesterolaemia to the 1998 Eu-
ropean goals for LDL-C at week 24. Compliance
was high and the use of compliance enhancement
tools did not increase the number and percentage
of patients achieving European goals for plasma
lipids. Rosuvastatin has a safety profile similar to
that of other statins and was well tolerated by pa-
tients.
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